US · Healthcare · Diagnostics & Research
EPS came in at -0.63 against a street estimate of -0.84 — a beat of 25.0%.
Analysts rate ENDRA Life Sciences Inc a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $25.00.
| Fund | Stake |
|---|---|
| Altium Capital Management, LP | 3.95% |
| Citadel Advisors Llc | 2.00% |
| Citizens Financial Group Inc | 1.89% |
| Geode Capital Management, LLC | 0.99% |
| Vanguard Fiduciary Trust Co | 0.67% |
| Vanguard Capital Management, LLC | 0.49% |
| Morgan Stanley - Brokerage Accounts | 0.24% |
| UBS Group AG | 0.00% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for ENDRA Life Sciences Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.